214 related articles for article (PubMed ID: 20368994)
1. Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS).
Twine SM; Petit MD; Fulton KM; House RV; Conlan JW
PLoS One; 2010 Apr; 5(4):e10000. PubMed ID: 20368994
[TBL] [Abstract][Full Text] [Related]
2. Identification of a live attenuated vaccine candidate for tularemia prophylaxis.
Mahawar M; Rabadi SM; Banik S; Catlett SV; Metzger DW; Malik M; Bakshi CS
PLoS One; 2013; 8(4):e61539. PubMed ID: 23613871
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Inner and Outer Membrane Proteins from
Post DMB; Slütter B; Schilling B; Chande AT; Rasmussen JA; Jones BD; D'Souza AK; Reinders LM; Harty JT; Gibson BW; Apicella MA
mBio; 2017 Oct; 8(5):. PubMed ID: 29018123
[No Abstract] [Full Text] [Related]
4. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
KuoLee R; Harris G; Conlan JW; Chen W
Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863
[TBL] [Abstract][Full Text] [Related]
5. An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes.
Pasetti MF; Cuberos L; Horn TL; Shearer JD; Matthews SJ; House RV; Sztein MB
Vaccine; 2008 Mar; 26(14):1773-85. PubMed ID: 18308432
[TBL] [Abstract][Full Text] [Related]
6. Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.
Hickey AJ; Hazlett KR; Kirimanjeswara GS; Metzger DW
Vaccine; 2011 Sep; 29(40):6941-7. PubMed ID: 21803089
[TBL] [Abstract][Full Text] [Related]
7. A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia.
Golovliov I; Twine SM; Shen H; Sjostedt A; Conlan W
PLoS One; 2013; 8(11):e78671. PubMed ID: 24236032
[TBL] [Abstract][Full Text] [Related]
8. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
Richard K; Mann BJ; Stocker L; Barry EM; Qin A; Cole LE; Hurley MT; Ernst RK; Michalek SM; Stein DC; Deshong P; Vogel SN
Clin Vaccine Immunol; 2014 Feb; 21(2):212-26. PubMed ID: 24351755
[TBL] [Abstract][Full Text] [Related]
9. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.
Mulligan MJ; Stapleton JT; Keitel WA; Frey SE; Chen WH; Rouphael N; Edupuganti S; Beck A; Winokur PL; El Sahly HM; Patel SM; Atmar RL; Graham I; Anderson E; El-Kamary SS; Pasetti MF; Sztein MB; Hill H; Goll JB;
Vaccine; 2017 Aug; 35(36):4730-4737. PubMed ID: 28750854
[TBL] [Abstract][Full Text] [Related]
10. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.
Drabick JJ; Narayanan RB; Williams JC; Leduc JW; Nacy CA
Am J Med Sci; 1994 Aug; 308(2):83-7. PubMed ID: 8042659
[TBL] [Abstract][Full Text] [Related]
11. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
Bakshi CS; Malik M; Mahawar M; Kirimanjeswara GS; Hazlett KR; Palmer LE; Furie MB; Singh R; Melendez JA; Sellati TJ; Metzger DW
Vaccine; 2008 Sep; 26(41):5276-88. PubMed ID: 18692537
[TBL] [Abstract][Full Text] [Related]
12. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.
Jia Q; Bowen R; Sahakian J; Dillon BJ; Horwitz MA
Infect Immun; 2013 May; 81(5):1550-61. PubMed ID: 23439306
[TBL] [Abstract][Full Text] [Related]
13. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
[No Abstract] [Full Text] [Related]
14. Models derived from in vitro analyses of spleen, liver, and lung leukocyte functions predict vaccine efficacy against the Francisella tularensis Live Vaccine Strain (LVS).
De Pascalis R; Chou AY; Ryden P; Kennett NJ; Sjöstedt A; Elkins KL
mBio; 2014 Apr; 5(2):e00936. PubMed ID: 24713322
[TBL] [Abstract][Full Text] [Related]
15. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.
Jia Q; Bowen R; Lee BY; Dillon BJ; Masleša-Galić S; Horwitz MA
Vaccine; 2016 Sep; 34(41):4969-4978. PubMed ID: 27577555
[TBL] [Abstract][Full Text] [Related]
16. Immunoproteomic analysis of the human antibody response to natural tularemia infection with Type A or Type B strains or LVS vaccination.
Fulton KM; Zhao X; Petit MD; Kilmury SL; Wolfraim LA; House RV; Sjostedt A; Twine SM
Int J Med Microbiol; 2011 Nov; 301(7):591-601. PubMed ID: 21873113
[TBL] [Abstract][Full Text] [Related]
17. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.
Kim TH; Pinkham JT; Heninger SJ; Chalabaev S; Kasper DL
J Infect Dis; 2012 Apr; 205(7):1056-65. PubMed ID: 21969334
[TBL] [Abstract][Full Text] [Related]
18. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
Baron SD; Singh R; Metzger DW
Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.
Green M; Choules G; Rogers D; Titball RW
Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452
[TBL] [Abstract][Full Text] [Related]
20. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.
Chen W; Shen H; Webb A; KuoLee R; Conlan JW
Vaccine; 2003 Sep; 21(25-26):3690-700. PubMed ID: 12922099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
